(NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S 500 average of 1.5%.

A big reason investors have liked the stock is the company's track record of increasing its payouts for years. And if you count the time when AbbVie was part of Abbott Laboratories, its streak of dividend increases technically goes back more than 50 consecutive years.

But there's a concerning trend that income investors should pay close attention to before deciding to add AbbVie to their portfolios.

Continue reading

Source Fool.com